Avanos Medical (AVNS) EBITDA (2013 - 2026)

Avanos Medical (AVNS) has 14 years of EBITDA data on file, last reported at $8.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 13.59% year-over-year to $8.9 million; the trailing twelve-month figure through Mar 2026 stood at -$63.0 million (up 83.84% YoY), and the FY2025 full-year result was -$61.6 million, up 84.45% from the prior year.
• EBITDA advanced to $8.9 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $16.6 million in Q4 2022 to a low of -$418.5 million in Q4 2024.
• A 5-year average of -$23.3 million and a median of $6.3 million in 2024 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 900.0% in 2024, while the deepest fall reached 3836.61% in 2024.
• Tracing AVNS's EBITDA over 5 years: stood at $16.6 million in 2022, then plunged by 32.53% to $11.2 million in 2023, then slumped by 3836.61% to -$418.5 million in 2024, then soared by 100.6% to $2.5 million in 2025, then soared by 256.0% to $8.9 million in 2026.
• Business Quant data shows AVNS's EBITDA at $8.9 million in Q1 2026, $2.5 million in Q4 2025, and $100000.0 in Q3 2025.